相关实验视频

Updated: Jul 27, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

这种SARS-CoV-2双价mRNA疫苗具有广泛的保护性,可以防止令人担忧的变种

Qinhai Ma¹, Man Li², Lin Ma³

¹State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Frontiers in immunology

|June 9, 2023

概括

一种新的双价mRNA疫苗,RBMRNA-405,结合了Delta和Omicron Spike蛋白质,显示了对SARS-CoV-2变种的广泛保护. 在临床前模型中,这种候选疫苗有效中和多个菌株,并防止病毒复制和肺损伤.

科学领域:

病毒学病毒学
疫苗学疫苗学疫苗学
免疫学免疫学免疫学

背景情况:

由于免疫逃避和疫苗有效性降低,SARS-CoV-2 Omicron变异的全球快速传播,其特点是众多的尖端蛋白突变,这构成了重大挑战.
现有的COVID-19预防策略受到新出现的SARS-CoV-2变种的挑战,突出了迫切需要更新的疫苗提供增强的保护.
目前针对高度突变变种的疫苗的有效性降低,需要开发新型疫苗配方.

研究的目的:

开发和评估一种新的双价mRNA疫苗,RBMRNA-405,旨在提供对SARS-CoV-2变种的更广泛保护.
在临床前环境中,与单价疫苗相比,评估双价疫苗的免疫性和预防性疗效.
为了研究中和抗体反应和对病毒挑战的保护作用.

主要方法:

开发一种双价mRNA疫苗 (RBMRNA-405),其中含有编码Delta和Omicron衍生的尖端蛋白的mRNA的1:1混合物.
在BALB/c小鼠中评估疫苗免疫性,重点关注抗体反应.
针对K18-ACE2小鼠的SARS-CoV-2变种挑战 (Omicron和Delta) 的预防疗效的比较,用于双价和单价疫苗.

主要成果:

RBMRNA-405引发了广泛的中和抗体反应,对抗祖先的武汉-胡-1菌株和多种SARS-CoV-2变体,包括三角形,欧米克朗,阿尔法,β和.
这种双价疫苗在被挑战的小鼠中有效地阻断了传染性病毒复制.
RBMRNA-405有效地预防了小鼠的肺损伤,这些小鼠受到Omicron或Delta变体的挑战.

结论:

双价mRNA疫苗RBMRNA-405证明了对各种SARS-CoV-2变异的有希望的广泛疗效.
RBMRNA-405显示了作为更新的COVID-19疫苗进一步临床开发的潜力.
这些发现支持使用双价疫苗的战略,以应对快速演变的病毒变体带来的挑战.

关键词:

这就是SARS-CoV-2病毒.这是一种双价mRNA疫苗.广泛的疗效效应的有效性.免疫性免疫性免疫性引起关注的变种 (VOCs)

更多相关视频

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

相关概念视频

Cross-reactivity

Cross-reactivity

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...